Annexon (ANNX) Stock Price & Analysis

ANNX$3.92-0.05 -1.26%
BiotechnologyGrowth Stock
Compare
Market cap$642.26MEnterprise value$657.30MRevenue (TTM)$0Market position—

Score

70
Bullish
Value
57
Quality
52
Growth
100

AI Analysis

Snapshot

Annexon is a growth-led story right now — Growth 100/100 is the pillar doing the heavy lifting (overall 70/100) in Biotechnology. In Biotechnology, that score mix is usable but not one-dimensional. Street targets still imply ~257% upside.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

57
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

100
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

52
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Annexon, Inc. (ANNX) last printed $3.92. Equity value is $642.26M. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

201720182019202020212022202320242025
$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00

About

Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The company targets this pathway to address specific disease mechanisms, such as those seen in antibody-mediated autoimmune disorders and complement-driven neurodegeneration. The company's developmental pipeline features several promising candidates. ANX005, a monoclonal antibody, is in advanced clinical testing, undergoing Phase II/III trials for Guillain-Barré syndrome, as well as Phase II trials for warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis. Another candidate, ANX009, is currently in Phase Ib studies for lupus nephritis. Additionally, ANX007 is progressing through Phase II clinical trials for the treatment of geographic atrophy, an eye disease. Further investigational assets include ANX105, a monoclonal antibody being developed for neurodegenerative indications, and ANX1502, an oral small molecule under investigation for specific autoimmune conditions. Annexon, Inc. was established in 2011 and operates from its headquarters in Brisbane, California.

Annexon (ANNX) Stock Price & Analysis

ANNX price $3.92 -0.05 -1.26%

Ticker
ANNX
Price
$3.92
Change
-0.05 -1.26%
Market cap
$642.26M
Forward P/E
3.57
Dividend yield
0.00%
Beta
1.44
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
70
Value
57
Quality
52
Growth
100

Stocklytics score rationale: value 57, quality 52, growth 100.

Fair value

ANNX fair value $33.74. Price $3.92. Price is 88% below fair value.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price.

Fair value is the earnings value from next-twelve-months EPS times 28.4, a blend of the industry median and the stock's own 10-year median. A cash-flow value is not available for this stock. How we calculate it →

Model uncertainty high for this stock

Compare ANNX

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2027-03-29—-0.28—15.46M
2027-03-08—-0.26—7.50M
2026-11-09-0.25-0.28—3.50M
2026-08-12-0.28-0.24—6.50M
2026-05-07-0.23-0.30—5.50M
2026-03-30-0.28-0.32—3.25M
2025-11-10-0.37-0.34——
2025-08-14-0.34-0.36——
2025-05-12-0.37-0.30——
2025-03-03-0.33-0.28——
2024-11-14-0.25-0.26——
2024-08-12-0.23-0.23——
2024-05-13-0.21-0.32——
2024-03-26-0.36-0.454.87M—
2023-11-13-0.43-0.50——
2023-08-07-0.47-0.54——
2023-05-08-0.52-0.52——
2023-03-06-0.48-0.52——
2022-11-03-0.51-0.87——
2022-08-08-0.96-0.94——
2022-05-09-0.92-1.00——
2022-03-01-0.97-0.90——
2021-11-09-0.93-0.88——
2021-08-16-0.82-0.68——
2021-05-17-0.68-0.60——
2021-03-25-0.61-0.42——
2020-11-16-0.77-0.34——
2020-09-08-28.87-0.53—1.84K
2020-07-24-0.94———
2019-12-31-0.68———
2019-09-30-0.78———
2019-06-30-0.72———
2019-03-31-0.66———
2018-12-31-11.01———
2018-09-30-9.68———
2018-06-30-12.78———
2018-03-31-12.78———

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2026-09-24Love DouglasBuy26.07K$3.8399.83K
2026-08-10Blumenkranz Mark S.Buy175.00K$5.39943.25K
2026-08-10Blumenkranz Mark S.Other0——
2026-06-11Waddill William D.Buy65.00K$4.70305.50K
2026-06-11Satter Muneer ABuy65.00K$4.70305.50K
2026-06-11JONES WILLIAM A JRBuy65.00K$4.70305.50K
2026-06-11Cockroft Bettina M.Buy65.00K$4.70305.50K
2026-06-11Choi JungBuy65.00K$4.70305.50K
2026-06-11Carson William H.Buy65.00K$4.70305.50K
2026-06-11Yednock TedBuy30.65K$1.8556.70K
2026-06-11Yednock TedSell30.65K$1.8556.70K
2026-05-28Satter Muneer ABuy613.50K$5.413.32M
2026-05-11Carson William H.Buy8.00K$5.7846.24K
2026-04-10Carson William H.Buy8.00K$6.2049.60K
2026-03-10Carson William H.Buy8.00K$5.6745.36K
2026-03-02Dananberg JamieSell5.82K$5.4331.60K
2026-03-02Overdorf MichaelSell4.34K$5.4223.52K
2026-03-02Yednock TedSell5.57K$5.4230.17K
2026-03-02ARTIS DEAN RICHARDSell5.89K$5.4332.00K
2026-03-02Lew JenniferSell5.57K$5.4230.16K
2026-02-19Love DouglasBuy1.25M$5.106.38M
2026-02-19Dananberg JamieBuy225.00K$5.101.15M
2026-02-19Dananberg JamieBuy56.25K——
2026-02-19Overdorf MichaelBuy250.00K$5.101.27M
2026-02-19Overdorf MichaelBuy62.50K——
2026-02-19ARTIS DEAN RICHARDBuy250.00K$5.101.27M
2026-02-19ARTIS DEAN RICHARDBuy62.50K——
2026-02-19Yednock TedBuy250.00K$5.101.27M
2026-02-19Yednock TedBuy62.50K——
2026-02-19Lew JenniferBuy250.00K$5.101.27M
2026-02-19Lew JenniferBuy62.50K——
2026-02-18Dananberg JamieSell5.29K$5.1026.98K
2026-02-18Lew JenniferSell7.85K$5.1140.12K
2026-02-18ARTIS DEAN RICHARDSell5.29K$5.1026.98K
2026-02-18Yednock TedSell7.86K$5.1140.15K
2026-02-18Overdorf MichaelSell6.22K$5.1031.75K
2025-12-30Carson William H.Buy4.12K$5.0220.66K
2025-12-01Choi JungBuy33.00K$4.19138.27K
2025-12-01Carson William H.Buy4.12K$4.4718.39K
2025-11-21Satter Muneer ABuy422.61K$4.281.81M
2025-11-20Satter Muneer ABuy400.00K$4.481.79M
2025-11-19Satter Muneer ABuy500.00K$3.941.97M
2025-11-18Satter Muneer ABuy500.00K$3.181.59M
2025-11-17Satter Muneer ABuy500.00K$2.991.50M
2025-10-30Carson William H.Buy4.12K$3.1713.04K
2025-09-30Carson William H.Buy4.12K$3.0512.55K
2025-09-02Carson William H.Buy4.12K$2.098.60K
2025-07-30Carson William H.Buy4.12K$2.4310.00K
2025-07-14Yednock TedSell1.12K$2.582.88K
2025-07-14Lew JenniferSell1.12K$2.582.88K
2025-07-14Overdorf MichaelSell853$2.612.23K
2025-06-30Carson William H.Buy4.12K$2.4610.12K
2025-06-05WIGGANS THOMAS GBuy55.00K$2.55140.25K
2025-06-05Satter Muneer ABuy55.00K$2.55140.25K
2025-06-05Waddill William D.Buy55.00K$2.55140.25K
2025-06-05Carson William H.Buy55.00K$2.55140.25K
2025-06-05Choi JungBuy55.00K$2.55140.25K
2025-06-05JONES WILLIAM A JRBuy55.00K$2.55140.25K
2025-06-05Cockroft Bettina M.Buy55.00K$2.55140.25K
2025-02-27ARTIS DEAN RICHARDBuy272.57K$2.50681.44K
2025-02-27Dananberg JamieBuy228.22K$2.50570.56K
2025-02-27Lew JenniferBuy272.57K$2.50681.44K
2025-02-27Love DouglasBuy1.30M$2.503.25M
2025-02-27Yednock TedBuy272.57K$2.50681.44K
2025-02-27Overdorf MichaelBuy272.57K$2.50681.44K
2025-02-18Dananberg JamieSell5.52K$2.9616.34K
2025-02-18ARTIS DEAN RICHARDSell5.51K$2.9716.38K
2025-02-18Yednock TedSell8.35K$2.9124.28K
2025-02-18Overdorf MichaelSell6.62K$2.9519.52K
2025-02-18Lew JenniferSell6.91K$2.9220.18K
2025-02-13Love DouglasSell5.02K$2.9514.81K
2025-02-13Overdorf MichaelSell1.43K$2.994.26K
2025-02-13Lew JenniferSell1.79K$2.985.32K
2025-02-13Yednock TedSell1.78K$2.995.33K
2025-01-09JONES WILLIAM A JRBuy88.00K$4.83425.04K
2025-01-09JONES WILLIAM A JROther0——
2025-01-06Love DouglasBuy37.99K$1.4153.56K
2025-01-06Love DouglasSell37.99K$1.4153.56K
2024-12-02Carson William H.Buy3.20K$5.3317.06K
2024-10-30Love DouglasBuy36.05K$1.8566.70K
2024-10-30Love DouglasBuy78.40K$1.85145.05K
2024-10-30Love DouglasSell36.05K$1.8566.70K
2024-10-15Yednock TedBuy5.41K$1.8510.01K
2024-10-15Yednock TedSell5.41K$7.4140.07K
2024-10-15Yednock TedSell5.41K$1.8510.01K
2024-10-01Carson William H.Buy3.20K$5.9719.10K
2024-09-19Yednock TedSell4.50K$7.1031.95K
2024-09-12Yednock TedSell5.50K$6.1633.88K
2024-09-05Yednock TedSell5.50K$5.6431.02K
2024-09-03Carson William H.Buy3.20K$5.4817.54K
2024-08-29Yednock TedSell5.50K$5.9532.73K
2024-08-01Carson William H.Buy3.20K$6.2419.97K
2024-07-15Overdorf MichaelSell784$6.024.72K
2024-07-15Lew JenniferSell1.10K$6.036.66K
2024-07-15Yednock TedSell1.11K$6.026.66K
2024-02-27ARTIS DEAN RICHARDBuy44.96K——
2024-02-27Dananberg JamieBuy44.96K——
2024-02-27Lew JenniferBuy44.96K——
2024-02-27Yednock TedBuy44.96K——
2024-02-27Overdorf MichaelBuy44.96K——

Institutional holders

Latest filed quarter: Q3 2026.

Institutions holding: 118, holders -110 vs prior quarter. Ownership 49.83%.

HolderSharesChangeChange %Value
FMR LLC26.91M7.39M+37.86%113.83M
BLACKROCK, INC.14.26M715.53K+5.28%60.30M
STATE STREET CORP9.49M-331.47K-3.37%40.15M
VANGUARD CAPITAL MANAGEMENT LLC7.87M999.66K+14.55%33.29M
SIREN, L.L.C.4.36M-99.09K-2.22%18.44M
GEODE CAPITAL MANAGEMENT, LLC4.25M211.76K+5.25%17.98M
QUBE RESEARCH & TECHNOLOGIES LTD4.11M1.36M+49.62%17.40M
MORGAN STANLEY3.21M65.33K+2.08%13.58M
VANGUARD PORTFOLIO MANAGEMENT LLC2.19M-55.09K-2.45%9.27M
NUVEEN, LLC2.00M-768.78K-27.80%8.44M
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP1.98M1.24M+168.25%8.37M
DIMENSIONAL FUND ADVISORS LP1.92M427.10K+28.52%8.14M
CANDRIAM S.C.A.1.68M483.84K+40.48%7.13M
MARSHALL WACE, LLP1.58M1.58MNew6.69M
KENNEDY CAPITAL MANAGEMENT LLC1.29M394.39K+43.90%5.47M
VANGUARD FIDUCIARY TRUST CO1.23M128.03K+11.58%5.22M
PANAGORA ASSET MANAGEMENT INC1.06M88.99K+9.19%4.47M
HRT FINANCIAL LP1.00M1.00MNew4.25M
JPMORGAN CHASE & CO962.64K-41.67K-4.15%3.98M
ENSIGN PEAK ADVISORS, INC739.33K-61.18K-7.64%3.13M
UBS GROUP AG653.16K30.06K+4.82%2.76M
SQUAREPOINT OPS LLC650.73K650.73KNew2.75M
DEUTSCHE BANK AG\603.17K-13.31K-2.16%2.55M
BANK OF NEW YORK MELLON CORP533.88K533.88KNew2.26M
JUMP FINANCIAL, LLC483.83K483.83KNew2.05M

Insights · Forecast · Financials · Learn

Stocklytics home · Screener